Codexis, NanoInk, HepaLife, Nabi Biopharmaceuticals and Calibrant Biosystems - People on the move
Biosystems have all had people on the move in the world of
Codexis has appointed Nicholas Green to the newly created position of president, Codexis Pharmaceuticals. Codexis is a developer of clean manufacturing processes, and in his new role Green will be responsible for the management and operations of the Pharmaceuticals division, overseeing the products and services for innovator and generics firms. Prior to joining Codexis, Green was CEO and managing director at Shasun Pharma Solutions, and held senior positions at Rhodia Pharma, Clariant Life Sciences and NIPA Biocides. Pharma anti-counterfeiting specialist NanoInk this week announced the appointment of James Hussey as the company's new CEO. Hussey will also join the firm's board of directors, and also continue as a member of the advisory board at his former company, Ovation Pharmaceuticals. Prior to joining Ovation, Hussey held senior positions at NeoPharm and Option Care, and began his career at Bristol-Myers Squibb. HepaLife, a US firm specialising in cell-based technologies, has named Christopher Kemp as the company's new vice president of R&D. As of February 1, Kemp will be responsible for the company's global research efforts and will drive development of technology strategy plans for HepaLife's cell-based platforms. Kemp formed contract manufacturer Kemp Biotechnologies in 1992 and acted as the firm's president for 15 years. Prior to this he worked for BioWhittaker and the National Institutes of Health. Raafat Fahim was named as the new president and CEO of Nabi Biopharmaceuticals this week, as the firm announced plans to investigate strategic alternatives for its business. Fahim succeeds Leslie Hudson, who has served as Nabi's interim president and CEO since February 2007. He joined the company in March 2003 as vice president of vaccine manufacturing operations and was named senior vice president of research, technical and manufacturing operations later that year. Most recently, Fahim held the position of COO and general manager of the biologics strategic business unit at the company. Prior to joining Nabi, Fahim spent the majority of his career at Sanofi Pasteur, the vaccines arm of Sanofi Aventis. Calibrant Biosystems has named its new COO, with Michael Salgaller taking up the position this week. Salgaller will be responsible for the company's worldwide development and operations, including ongoing drug development programmes and external collaborations. Salgaller was an advisor to Calibrant in 2005-2006, and prior to joining the company was on the investment team at Toucan Capital. Prior to this Salgaller held senior positions with Northwest Biotherapeutics and a number of biotech firms, as well as time with the National Institutes of Health.